After experimentation with LLMs, engineering leaders are discovering a hard truth: better models alone don’t deliver better ...
See how ZX Series Interactive Displays bring AI, collaboration, and Google-ready tools into classrooms, helping teachers ...
PURE: How 100% Kotton Is Redefining the Sound of Luxury House Music Miami, United States – March 30, 2026 / Kotton Grammer / ​​ FOR IMMEDIATE RELEASE Media Contact: Kotton Grammer / 100% Kotton Email: ...
On March 20, 2026, a patent expired in India that is set to change the country's weight loss and diabetes drug market. Semaglutide, the molecule behind Novo Nordisk's blockbuster drugs Ozempic and ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Five weeks after the Trump administration announced the launch of TrumpRX, a recent healthcare poll shows only a third of surveyed Americans have heard of the platform, and an even smaller percentage ...
Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...
The FDA has approved a generic version of fluticasone propionate (marketed as Flovent HFA), according to a statement issued on March 3. The approval extends the accessibility of the medication, ...
After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.
Muriel, from the Auxiliary of Social Life, works at the home of Mr. T, who has multiple sclerosis, in Pas de Calais, France, on June 11, 2023. (Astier / BSIP via AFP) (CN) — For people living with ...
I open my emails to find yet another message from a patient about their amphetamine-dextroamphetamine (the generic form of Aderall) no longer working. Dr. Plutchik, my meds no longer seem to be ...